| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.7M+8.3% | $4.3M+79.0% | $2.4M+544.0% | $377K-24.6% | $500K | — |
| Cost of revenue | $6.7M-6.0% | $7.1M+18.7% | $6.0M+65.4% | $3.6M+517.8% | $585K | — |
| Sales and marketing | $17.7M+7.6% | $16.5M+0.4% | $16.4M+1.7% | $16.1M+206.7% | $5.3M+303.1% | $1.3M |
| General and administrative | $23.9M+18.4% | $20.2M+4.7% | $19.3M-19.7% | $24.0M+87.6% | $12.8M+734.1% | $1.5M |
| Amortization of acquired intangible assets | $421K-38.8% | $688K-66.0% | $2.0M+22.6% | $1.6M | $0 | — |
| Research and development | $5.7M-5.2% | $6.0M-17.4% | $7.3M-35.6% | $11.3M+21.1% | $9.3M+70.8% | $5.4M |
| Total operating expenses | $54.3M+7.8% | $50.4M-1.0% | $50.9M-10.1% | $56.6M+102.8% | $27.9M+237.2% | $8.3M |
| Operating loss | -$49.6M-7.8% | -$46.1M+5.0% | -$48.5M+13.8% | -$56.3M-105.2% | -$27.4M-231.1% | -$8.3M |
| Interest income | $386K+19.9% | $322K-24.1% | $424K+381.8% | $88K | — | — |
| Interest expense | -$22K+15.4% | -$26K+93.8% | -$416K-5100.0% | -$8K | — | — |
| Change in fair value - Senior Secured Convertible Note | -$7.7M-241.9% | $5.4M+281.0% | -$3.0M | — | — | — |
| Debt extinguishments loss - Senior Secured Convertible Note | $0+100.0% | -$5.2M-19773.1% | -$26K | — | — | — |
| Equity issuance cost extinguishment | -$1.1M | $0 | — | — | — | — |
| Other income (expense), net | -$8.4M-1700.4% | $523K+112.5% | -$4.2M-5330.0% | $80K | — | — |
| Loss before provision for income tax | -$58.0M-27.4% | -$45.5M+13.6% | -$52.7M+6.2% | -$56.2M-100.1% | -$28.1M-239.1% | -$8.3M |
| Provision for income taxes | $0 | $0 | — | — | — | — |
| Net loss attributable to Lucid Diagnostics Inc. | -$58.0M-27.4% | -$45.5M+13.6% | -$52.7M+6.2% | -$56.2M-100.1% | -$28.1M-239.1% | -$8.3M |
| Net loss attributable to Lucid Diagnostics Inc. common stockholders | -$70.6M-33.1% | -$53.0M-0.7% | -$52.7M | — | — | — |
| Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted (in dollars per share) | -$0.69+34.3% | -$1.05+16.7% | -$1.26+18.7% | -$1.55-2.6% | -$1.51 | — |
| Weighted average common shares outstanding, basic and diluted (in shares) | 101.95B+101.8% | 50.52B+21.0% | 41.76B+15.4% | 36.17B+94.4% | 18.60B | — |
| Series A and A-1 Preferred Stock [Member] | ||||||
| Dividends | -$12.6M | $0 | — | — | — | — |
| Series B and B-1 Preferred Stock [Member] | ||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.